Casdatifan, an HIF-2α inhibitor, showed a 33% objective response rate in ccRCC patients at a 100 mg daily dose. The drug targets hypoxia-inducible factor-2 alpha to disrupt tumor-promoting mechanisms ...
BOSTON--(BUSINESS WIRE)--Bicara Therapeutics, a clinical-stage biotechnology company developing transformative bifunctional therapies for patients with solid tumors, today announced the presentation ...
Vigil Neuroscience reported positive Phase 1 trial results for VG-3927 and plans a Phase 2 trial in Q3 2025. Vigil Neuroscience, Inc. announced promising outcomes from a Phase 1 clinical trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback